News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
80
Sources here
5
Companies here
1
Search results Stored financial headlines

Active search

80 matching headlines

Ticker or company: AZN1NMain company stories
Clear
Latest

seekingalpha.com Market update

AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo

[A big sign with AstraZeneca logotype outside the entrance.] Wirestock * AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) is discontinuing its eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer after an independent committee concluded the drug was unlikely to meet either primary endpoint, according to a statement on Monday. * The IDMC concluded that the volrustomig …

Main company 🇲🇽 Mexico
Read at seekingalpha.com
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
nasdaq.com Deals and strategy Main company 🇲🇽 Mexico

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Analyst action Main company 🇲🇽 Mexico

How AstraZeneca’s $400bn deal unravelled

One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇲🇽 Mexico

Do Options Traders Know Something About AstraZeneca Stock We Don't?

Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Hedge Funds are Bullish on AstraZeneca PLC (AZN)

AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?

It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca (LSE:AZN) Merger Talk Fades, Is The Stock Undervalued?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AstraZeneca (LSE:AZN) is back in focus after a senior source told Reuters that there are no ongoing merger discussions with Bristol Myers Squibb, reversing earlier …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
uk.finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

How the FTSE became a ‘departure lounge’ for British companies

On holiday in Devon this summer, Charles Hall felt a familiar sinking feeling. The most senior analyst at City stockbroker Peel Hunt had just read that AstraZeneca held talks with US pharmaceutical giant Bristol Myers Squibb about a potential merger. It reignited concerns that …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AZN rebounds after report dismisses AstraZeneca-Bristol Myers merger speculation

Astra Zeneca logo on building ©Adobe Stock Images AstraZeneca (NASDAQ:AZN) shares climbed around 6% on Wednesday after Reuters reported that there are "no discussions" between the company and Bristol Myers Squibb (NYSE:BMY) regarding a potential merger, contradicting recent speculation that had unsettled investors. The …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

By Maggie Fick and Sabrina Valle Aug 5 (Reuters) - There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a ‌potential deal, a senior source close to the matter told ‌Reuters on Wednesday, quashing the prospect of a mooted mega merger …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AZN spikes 6% after report it denies AstraZeneca-BMS merger talks

Investing.com - AstraZeneca shares surged approximately 6% on Wednesday after a senior source told Reuters there are "no discussions" between AstraZeneca and Bristol Myers Squibb over a potential deal, flatly quashing reports of a merger that would have created a pharmaceutical giant worth nearly …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says

Bristol Myers Squibb's (BMY) reported merger discussions with AstraZeneca (AZN) will unlikely result PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

Brokers split on AstraZeneca merger talk as shares recover some ground

Brokers split on AstraZeneca merger talk as shares recover some ground Proactive uses images sourced from Shutterstock Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca (LSE:AZN) Is In Merger Talks With Bristol Myers For $400 Billion

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇲🇽 Mexico

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).SOPHiA GENETICS Logo This multi-year collaboration agreement will advance …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol-Myers Squibb (BMY) shares opened higher on Monday following reports that the U.S. pharma giant held preliminary merger talks with UK rival AstraZeneca (AZN). If finalized, this reported transaction would create the world's largest drugmaker (by revenue) with a market cap approaching $400 billion. …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company developing cancer, rare-disease and other medicines, plunged approximately 7.7% in Monday's U.S. regular-session trading as investors assessed reported merger discussions with Bristol Myers Squibb (NYSE:BMY), a U.S. biopharmaceutical company. A combination could …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Analyst action Main company 🇲🇽 Mexico

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

Quick Read BMY's existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN acquisition target, Holz argues. Eli Lilly's $1 trillion market cap dwarfs all pharma rivals, pushing companies like Merck to pursue deals ahead of looming patent cliffs. …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca Investors See Little Logic in Bristol Tie-Up

AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. View Comments

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
uk.finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

Stocks mixed as AstraZeneca merger talk dents FTSE 100

The FTSE 100 underperformed European peers on Monday as heavy falls in AstraZeneca outweighed more optimistic noises in the Middle East. The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70. The FTSE 250 ended up 249.75 points, 1.0%, at 24,224.77, while the …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca Nosedives On A Rumored Megamerger; Is $160 Billion Enough?

AstraZeneca stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb. Continue Reading

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?

Investing.com - AstraZeneca are trading roughly 9% lower on Monday after the Financial Times first reported, followed by Reuters and Bloomberg, that the British drugmaker held preliminary discussions with Bristol Myers Squibb about a combination that would create a nearly $400 billion pharmaceutical giant. …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇲🇽 Mexico

Top Midday Stories: Amazon Market Cap Hits $3 Trillion; AstraZeneca, Bristol Myers Squibb Reportedly Discuss $400 Billion Combination

All three major US stock indexes were up in late-morning trading Monday after President Donald Trump PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

Astra Buying Bristol Makes No Sense, Fazeli Says

AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers. Sam Fazeli of Bloomberg Intelligence says a takeover would make no sense. View Comments

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

European Stocks Close Mostly Higher in Monday Trading; AstraZeneca Reportedly in Merger Talks With Bristol Myers

European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca Stock Nosedives On Mega-Merger Rumor

AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb. Continue Reading

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇲🇽 Mexico

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

AIM ImmunoTech Inc. Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the final subject …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca Weighs a Deal Its CEO Said It Didn't Need

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the UK drugmaker and the country's second most valuable listed company, fell 6.27% in London after news that it has held talks with Bristol Myers Squibb (NYSE:BMY) about a combination valued near $400 billion, according to …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Reports indicate AstraZeneca and Bristol-Myers Squibb are in early talks regarding a potential merger. …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
uk.finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca in talks over £300bn mega-merger with US rival – reports

AstraZeneca has held talks with US rival Bristol Myers Squibb over a merger which could create a drugs giant worth more than £300 billion, according to reports. The two pharmaceutical firms have held discussions over a potential tie-up in recent months, the Financial Times …

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Mexico Business News Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca, Bristol Myers Squibb Explore US$400 Billion Merger

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. Continue Reading

AZN1N main company
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9% AZN1N stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context